Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vertex Pharmaceuticals Inc (VRTX)  
$437.49 8.90 (2.08%) as of 4:30 Wed 5/15


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 260,040,000
Market Cap: 113.76(B)
Last Volume: 1,059,413 Avg Vol: 1,615,310
52 Week Range: $323.57 - $446.08
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 400 MIDCAP     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  543
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 45,457 125,099 237,443 597,852
Total Sell Value $19,193,323 $51,578,069 $92,174,963 $199,924,371
Total People Sold 8 11 14 18
Total Sell Transactions 19 38 60 128
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 3266
  Page 11 of 131  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-11-07 4 OE $187.53 $244,352 D/D 1,303 37,380     -
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2022-11-02 4 AS $310.10 $100,045 D/D (320) 38,104 -3%     
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2022-11-01 4 D $312.84 $240,261 D/D (768) 38,424     -
   Bhatia Sangeeta N. Director   –       •      –    2022-10-24 4 AS $310.00 $192,510 D/D (621) 4,040 -8%     
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2022-10-18 4 AS $300.02 $537,860 D/D (1,791) 39,192 -3%     
   Biller Jonathan EVP and Chief Legal Officer   •       –      –    2022-09-19 4 A $0.00 $0 D/D 5,294 5,294     -
   Arbuckle Stuart A EVP, COO   •       –      –    2022-08-15 4 AS $300.30 $6,738,991 D/D (22,173) 45,278 -6%     
   Arbuckle Stuart A EVP, COO   •       –      –    2022-08-15 4 OE $155.57 $1,022,250 D/D 6,571 67,451     -
   Kewalramani Reshma CEO & President   •       •      –    2022-08-15 4 AS $305.06 $3,565,846 D/D (11,689) 99,598 -6%     
   Liu Joy SVP, General Counsel   •       –      –    2022-08-15 4 AS $300.26 $1,138,723 D/D (3,747) 9,605 -6%     
   Liu Joy SVP, General Counsel   •       –      –    2022-08-10 4 AS $300.32 $10,812 D/D (36) 13,352 -2%     
   Arbuckle Stuart A EVP, COO   •       –      –    2022-08-10 4 AS $300.32 $54,073 D/D (180) 60,880 -2%     
   Arbuckle Stuart A EVP, COO   •       –      –    2022-08-10 4 OE $155.57 $9,956 D/D 64 61,060     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2022-08-09 4 AS $297.54 $418,557 D/D (1,400) 46,090 -2%     
   Arbuckle Stuart A EVP, COO   •       –      –    2022-08-09 4 AS $300.53 $1,710,817 D/D (5,690) 60,996 -2%     
   Arbuckle Stuart A EVP, COO   •       –      –    2022-08-09 4 OE $155.57 $299,628 D/D 1,926 66,686     -
   Liu Joy SVP, General Counsel   •       –      –    2022-08-09 4 AS $300.00 $283,800 D/D (946) 13,388 -2%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-08-08 4 AS $290.32 $381,469 D/D (1,304) 36,077 -1%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-08-08 4 OE $187.53 $244,539 D/D 1,304 37,381     -
   Bhatia Sangeeta N. Director   –       •      –    2022-08-08 4 AS $290.18 $181,972 D/D (621) 4,661 -1%     
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2022-08-01 4 D $276.62 $211,891 D/D (766) 40,983     -
   Bhatia Sangeeta N. Director   –       •      –    2022-07-29 4 AS $276.65 $173,116 D/D (621) 5,282 11%     
   Leiden Jeffrey M Executive Chairman   •       •      –    2022-07-25 4 AS $279.44 $37,164,481 D/D (132,079) 2,423 12%     
   Leiden Jeffrey M Executive Chairman   •       •      –    2022-07-25 4 OE $91.05 $5,494,139 D/D 60,342 134,502     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-07-19 4 AS $286.72 $5,156,730 D/D (17,865) 36,077 9%     
  3266 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 11 of 131
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us